News Search Results
Jan 13, 2025, 10:00 ET Vevo Therapeutics to Open Source Milestone Tahoe-100M Dataset
FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Vevo Therapeutics, a biotechnology company using its Mosaic technology and next-generation AI to uncover better drugs for more patients, announced today that it will open source its
More news about: Vevo Therapeutics
Jan 13, 2025, 10:00 ET EDETEK Unveils Revolutionary Life Sciences R&D Cloud for Clinical Development
solutions company that provides high-quality Artificial Intelligence-powered technology platforms and related clinical services to pharmaceutical, biotechnology, and medical device companies. With a global presence across four continents and serving clinical development globally, EDETEK's commitment to excellence
More news about: EDETEK, Inc.
Jan 13, 2025, 09:30 ET A28 Therapeutics and GATC Health Announce Comprehensive AI-Powered Analysis, Predicting Efficacy, Safety, and Potential Off-Target Effects of A28's AT-101 Cancer Drug Candidate
A28 Therapeutics is a clinical stage biotechnology company developing first in class targeted oncolytic peptides (TOPs), for treatment of cancer. A28's lead candidate, AT-101, is currently being
More news about: GATC Health; A28 Therapeutics
Jan 13, 2025, 09:00 ET Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
Jan. 13, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive agreement for Lilly to acquire Scorpion's PI3Kα inhibitor
More news about: Eli Lilly and Company
Jan 13, 2025, 09:00 ET Spear Bio Secures FDA Breakthrough Device Designation for its Novel pTau 217 Blood Test, Advancing Scalable Solutions for Early Alzheimer's Disease Diagnosis
WOBURN, Mass., Jan. 13, 2025 /PRNewswire/ -- Spear Bio Inc., a biotechnology company pioneering next-generation ultra-sensitive immunoassays, today announced that its pTau 217 blood test has been granted Breakthrough Device
More news about: Spear Bio
Jan 13, 2025, 08:45 ET TCBP to Present at Sequire Investor Summit 2025
Jan. 13, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that CEO Bryan Kobel will
More news about: TC BioPharm
Jan 13, 2025, 08:38 ET RTI International Invests in Healthcare Technology Companies b.well Connected Health and BEKhealth
International is a fantastic research partner for us." RTI Health Solutions provides consulting and research expertise to pharmaceutical, biotechnology, diagnostics and medical device companies. The institute's investments in b.well Connected Health and BEKhealth add to its development portfolio
More news about: RTI International
Jan 13, 2025, 08:31 ET AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
YouTube. ABOUT REGENXBIO Inc. REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development
More news about: AbbVie
Jan 13, 2025, 08:30 ET Cresilon Announces U.S. Nationwide Launch of TRAUMAGEL
Jan. 13, 2025 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced the U.S. commercial launch of TRAUMAGEL®, a revolutionary plant-based hemostatic
More news about: Cresilon
Jan 13, 2025, 08:05 ET Rigel Provides Business Update and 2025 Outlook
Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product sales
More news about: Rigel Pharmaceuticals, Inc.
Jan 13, 2025, 08:00 ET Hemab Therapeutics Expands Management Team with Appointment of Kate Madigan, MD, as Chief Medical Officer and Announce Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Mass., Jan. 13, 2025 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the appointment of
More news about: Hemab Therapeutics
Jan 13, 2025, 08:00 ET Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts
Jan. 13, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy
More news about: Spyre Therapeutics, Inc.
Jan 13, 2025, 08:00 ET Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
potential approval of donidalorsen in hereditary angioedema later this year, Ionis has entered a new chapter as a fully integrated commercial-stage biotechnology company that independently brings our innovative medicines to patients," said Brett P. Monia, Ph.D., chief executive
More news about: Ionis Pharmaceuticals, Inc.
Jan 13, 2025, 07:30 ET Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones
Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may
More news about: Elevation Oncology
Jan 13, 2025, 06:30 ET Novel Therapies for AML and other Cancers
Taiwan, Orient EuroPharma, Orient Pharma, OP NanoPharma, and OEPI are divisions of a full-service pharmaceutical company specializing in oncology, biotechnology, and drug commercialization. With expertise in drug development, manufacturing, and market expansion, OEP partners with innovative biotech firms
More news about: Cambium Oncology
Jan 13, 2025, 01:00 ET Roche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma
Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics
More news about: Roche
Jan 12, 2025, 19:00 ET CMU and Healthcare System Secures Unprecedented 17 Awards at the 2024 Taiwan National Innovation Awards
Awards, and nine Clinical Innovation Awards. This unparalleled success cements CMU and Healthcare System's position as a trailblazer in biotechnology, smart healthcare, and innovative medical devices.
More news about: China Medical University Hospital
Jan 12, 2025, 17:48 ET Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
Appendix 3B lodged with the ASX today for further information. About ImaginAb, Inc. ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of radiopharmaceutical and imaging agent products. These patented products contain engineered antibodies
More news about: Telix Pharmaceuticals Limited
Jan 12, 2025, 12:00 ET IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance
Executive Officer, IDEAYA Biosciences, followed by analyst-hosted Q&A with Anupam Rama, Managing Director, US SMID Biotechnology Equity Research, J.P. Morgan2025 Corporate Guidance to be Presented at the 43rd Annual J.P. Morgan Healthcare Conference:
More news about: IDEAYA Biosciences, Inc.
Jan 11, 2025, 10:56 ET CES 2025: The Global Stage for Innovation, Connecting the World, Creating the Future
the smart living experience. CES has cemented itself as a premier convenor for the healthcare industry, bringing together trailblazers to explore biotechnology, telehealth, and wellness advancements that enhance patient care and longevity. Attendees celebrated the vibrant and dynamic environment that underscored
More news about: Consumer Technology Association
Jan 10, 2025, 21:59 ET CES 2025: The Global Stage for Innovation, Connecting the World, Creating the Future
the smart living experience. CES has cemented itself as a premier convenor for the healthcare industry, bringing together trailblazers to explore biotechnology, telehealth, and wellness advancements that enhance patient care and longevity. Attendees celebrated the vibrant and dynamic environment that underscored
More news about: Consumer Technology Association
Jan 10, 2025, 19:59 ET Canary Cure's Game-Changing Obesity Therapy Burns Fat and Protects Muscle
Investigational New Drug (IND) application by Q3 2025 and begin Phase 1 clinical trials in 2026. About Canary Cure Canary Cure, a biotechnology company, is developing revolutionary RNA therapeutics targeting obesity and metabolic disorders. The company's proprietary siRNA technology platform
More news about: Canary Cure
Jan 10, 2025, 14:25 ET REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
e-mail at [email protected]. CASE ALLEGATIONS: Regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others.
More news about: Robbins Geller Rudman & Dowd LLP
Jan 10, 2025, 12:59 ET Virion Therapeutics Completes Enrollment of First 2 Cohorts of Phase 1b Chronic Hepatitis B Trial of VRON-0200 For HBV Functional Cure
Jan. 10, 2025 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize first-in-class, checkpoint modifiers, today announced that its Phase
More news about: Virion Therapeutics, LLC
Jan 10, 2025, 12:46 ET Chronic Disease Management: Innovations in Therapeutics, Devices, and Global Markets
is rising, due to poor diet, lack of exercise, and stress, particularly in urbanized developing countries. Technological Advances: Biotechnology and medical devices, such as wearables and telehealth, improve chronic disease management and care efficiency. Government Support:
More news about: BCC Research LLC